Human Vaccines & Immunotherapeutics最新文献_第4页

Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France. 法国首批接受西帕维巴特作为 COVID-19 暴露前预防早期治疗的免疫力低下患者的特征。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-08-14 DOI: 10.1080/21645515.2024.2387221

Paul Loubet, Benjamin Gaborit, Mathilde Salpin, Hèlene Gardeney, Ilies Benotmane, Thomas Systchenko

引用次数: 0

Neutralization potency of the 2023-24 seasonal influenza vaccine against circulating influenza H3N2 strains. 2023-24 年度季节性流感疫苗对流行 H3N2 流感病毒株的中和效力。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-08-29 DOI: 10.1080/21645515.2024.2380111

Xiande Huang, Ziqi Cheng, Yake Lv, Weixuan Li, Xiaoyu Liu, Weijin Huang, Chenyan Zhao

{"title":"Neutralization potency of the 2023-24 seasonal influenza vaccine against circulating influenza H3N2 strains.","authors":"Xiande Huang, Ziqi Cheng, Yake Lv, Weixuan Li, Xiaoyu Liu, Weijin Huang, Chenyan Zhao","doi":"10.1080/21645515.2024.2380111","DOIUrl":"10.1080/21645515.2024.2380111","url":null,"abstract":"Seasonal influenza is a severe disease that significantly impacts public health, causing millions of infections and hundreds of thousands of deaths each year. Seasonal influenza viruses, particularly the H3N2 subtype, exhibit high antigenic variability, often leading to mismatch between vaccine strains and circulating strains. Therefore, rapidly assessing the alignment between existing seasonal influenza vaccine and circulating strains is crucial for enhancing vaccine efficacy. This study, based on a pseudovirus platform, evaluated the match between current influenza H3N2 vaccine strains and circulating strains through cross-neutralization assays using clinical human immune sera against globally circulating influenza virus strains. The research results show that although mutations are present in the circulating strains, the current H3N2 vaccine strain still imparting effective protection, providing a scientific basis for encouraging influenza vaccination. This research methodology can be sustainably applied for the neutralization potency assessment of subsequent circulating strains, establishing a persistent methodological framework.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11364067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Community based participatory research as a promising practice for addressing vaccine hesitancy, rebuilding trust and addressing health disparities among racial and ethnic minority communities. 以社区为基础的参与式研究是解决疫苗接种犹豫、重建信任和解决少数种族和少数族裔社区健康差距问题的一种可行做法。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-03-18 DOI: 10.1080/21645515.2024.2326781

Sophie E O'Bryan, Fatima Muñoz, David Smith, Adriana Bearse, Blanca Melendrez, Biren Kamdar, Cynthia James-Price, Daniel Ramirez, Argentina E Servin

{"title":"Community based participatory research as a promising practice for addressing vaccine hesitancy, rebuilding trust and addressing health disparities among racial and ethnic minority communities.","authors":"Sophie E O'Bryan, Fatima Muñoz, David Smith, Adriana Bearse, Blanca Melendrez, Biren Kamdar, Cynthia James-Price, Daniel Ramirez, Argentina E Servin","doi":"10.1080/21645515.2024.2326781","DOIUrl":"10.1080/21645515.2024.2326781","url":null,"abstract":"The COVID-19 pandemic disproportionately affected racial and ethnic minority communities across the United States (U.S.). Despite the disproportionate burden of COVID-19 faced by communities of color, Black and Hispanic communities are less likely to be fully vaccinated than White non-Hispanic Persons. Health inequity and vaccine hesitancy are complex phenomena that require multilevel responses tailored to the unique needs of each community, a process that inherently necessitates a high level of community engagement in order to develop the most effective health interventions. Building on the principles of community based participatory research (CBPR) and with the support of the National Institutes of Health (NIH), Project 2VIDA! was born. A multidisciplinary collaborative of academic researchers, community members, and clinicians whose aim is to foster sustainable partnerships to reduce the burden of COVID-19 in Hispanic and Black communities across Southern California. Our model was designed to meet our community members where they were - whether on their lunch break or picking their children from school. This CBPR model has been well received by community members. Future health interventions focused on reducing health disparities should prioritize the role of the community, leverage the voices of key community partners, and be grounded in equitable power sharing.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10950264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A highly neutralizing human monoclonal antibody targeting a novel linear epitope on staphylococcal enterotoxin B. 针对葡萄球菌肠毒素 B 上的新型线性表位的高中和性人类单克隆抗体。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-06-10 DOI: 10.1080/21645515.2024.2360338

Hongyin Fan, Liqun Zhao, Weiwei Wang, Feng Yu, Haiming Jing, Yun Yang, Xiaoli Zhang, Zhuo Zhao, Qiang Gou, Weijun Zhang, Quanming Zou, Jinyong Zhang, Hao Zeng

{"title":"A highly neutralizing human monoclonal antibody targeting a novel linear epitope on staphylococcal enterotoxin B.","authors":"Hongyin Fan, Liqun Zhao, Weiwei Wang, Feng Yu, Haiming Jing, Yun Yang, Xiaoli Zhang, Zhuo Zhao, Qiang Gou, Weijun Zhang, Quanming Zou, Jinyong Zhang, Hao Zeng","doi":"10.1080/21645515.2024.2360338","DOIUrl":"10.1080/21645515.2024.2360338","url":null,"abstract":"Staphylococcal Enterotoxin B (SEB), produced by Staphylococcus aureus (S. aureus), is a powerful superantigen that induces severe immune disruption and toxic shock syndrome (TSS) upon binding to MHC-II and TCR. Despite its significant impact on the pathogenesis of S. aureus, there are currently no specific therapeutic interventions available to counteract the mechanism of action exerted by this toxin. In this study, we have identified a human monoclonal antibody, named Hm0487, that specifically targets SEB by single-cell sequencing using PBMCs isolated from volunteers enrolled in a phase I clinical trial of the five-antigen S. aureus vaccine. X-ray crystallography studies revealed that Hm0487 exhibits high affinity for a linear B cell epitope in SEB (SEB138-147), which is located distantly from the site involved in the formation of the MHC-SEB-TCR ternary complex. Furthermore, in vitro studies demonstrated that Hm0487 significantly impacts the interaction of SEB with both receptors and the binding to immune cells, probably due to an allosteric effect on SEB rather than competing with receptors for binding sites. Moreover, both in vitro and in vivo studies validated that Hm0487 displayed efficient neutralizing efficacy in models of lethal shock and sepsis induced by either SEB or bacterial challenge. Our findings unveil an alternative mechanism for neutralizing the pathogenesis of SEB by Hm0487, and this antibody provides a novel strategy for mitigating both SEB-induced toxicity and S. aureus infection.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141301966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Broadening sarbecovirus neutralization with bispecific antibodies combining distinct conserved targets on the receptor binding domain. 利用结合受体结合域上不同保守靶点的双特异性抗体拓宽肉瘤病毒的中和作用。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-08-20 DOI: 10.1080/21645515.2024.2388344

Denise Guerra, Laura Radić, Mitch Brinkkemper, Meliawati Poniman, Lara van der Maas, Jonathan L Torres, Andrew B Ward, Kwinten Sliepen, Janke Schinkel, Rogier W Sanders, Marit J van Gils, Tim Beaumont

{"title":"Broadening sarbecovirus neutralization with bispecific antibodies combining distinct conserved targets on the receptor binding domain.","authors":"Denise Guerra, Laura Radić, Mitch Brinkkemper, Meliawati Poniman, Lara van der Maas, Jonathan L Torres, Andrew B Ward, Kwinten Sliepen, Janke Schinkel, Rogier W Sanders, Marit J van Gils, Tim Beaumont","doi":"10.1080/21645515.2024.2388344","DOIUrl":"10.1080/21645515.2024.2388344","url":null,"abstract":"Monoclonal neutralizing antibodies (mAbs) are considered an important prophylactic against SARS-CoV-2 infection in at-risk populations and a strategy to counteract future sarbecovirus-induced disease. However, most mAbs isolated so far neutralize only a few sarbecovirus strains. Therefore, there is a growing interest in bispecific antibodies (bsAbs) which can simultaneously target different spike epitopes and thereby increase neutralizing breadth and prevent viral escape. Here, we generate and characterize a panel of 30 novel broadly reactive bsAbs using an efficient controlled Fab-arm exchange protocol. We specifically combine some of the broadest mAbs described so far, which target conserved epitopes on the receptor binding domain (RBD). Several bsAbs show superior cross-binding and neutralization compared to the parental mAbs and cocktails against sarbecoviruses from diverse clades, including recent SARS-CoV-2 variants. BsAbs which include mAb COVA2-02 are among the most potent and broad combinations. As a result, we study the unknown epitope of COVA2-02 and show that this mAb targets a distinct conserved region at the base of the RBD, which could be of interest when designing next-generation bsAb constructs to contribute to a better pandemic preparedness.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11340772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to comment on "A bibliometric analysis of vaccination against atherosclerosis". 对 "动脉粥样硬化疫苗接种的文献计量分析 "评论的回应。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-08-14 DOI: 10.1080/21645515.2024.2377851

Bochao Jia, Rui Wei, Chenlu Yuan, Tao Cheng, Shuai Shi, Yuguang Chu, Yuanhui Hu

引用次数: 0

Cost-effectiveness analysis of vaccination strategies against meningococcal disease for children under nine years of age in China. 中国九岁以下儿童脑膜炎球菌病疫苗接种策略的成本效益分析。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-02-13 DOI: 10.1080/21645515.2024.2313872

Haonan Zhang, Haijun Zhang, Hai Fang

{"title":"Cost-effectiveness analysis of vaccination strategies against meningococcal disease for children under nine years of age in China.","authors":"Haonan Zhang, Haijun Zhang, Hai Fang","doi":"10.1080/21645515.2024.2313872","DOIUrl":"10.1080/21645515.2024.2313872","url":null,"abstract":"Meningococcal vaccination strategies in China are intricate, including multiple vaccines targeting different serogroups. The current National Immunization Program (NIP) includes two polysaccharide vaccines for serogroups A and C (MPV-A and MPV-AC), covering limited serogroups and requiring adaptation. This study aims to evaluate the cost-effectiveness of replacing the current strategy with alternative strategies utilizing non-NIP vaccines to inform policy decisions. From a societal perspective, a decision tree-Markov model was constructed to simulate the economic and health consequences of meningococcal disease in a 2019 birth cohort with four vaccination strategies. Epidemiology, vaccine efficacy, cost, and other parameters were derived from previous studies. We conducted sensitivity analyses to assess the robustness of the findings and explored prices for non-NIP vaccines that enable cost-effective strategies. Compared to the current strategy, alternative strategies using quadrivalent polysaccharide vaccine (MPV-4), bivalent conjugate vaccine (MCV-AC), and quadrivalent conjugate vaccine (MCV-4) could avoid 91, 286, and 455 more meningococcal cases. The ICERs were estimated at approximately $250 thousand/QALY, $450 thousand/QALY, and $1.5 million/QALY, all exceeding the threshold of three times GDP per capita. The alternative strategies were not cost-effective. However, if vaccine prices were reduced to $3.9 for MPV-4, $9.9 for MCV-AC, and $12 for MCV-4, the corresponding strategy would be cost-effective. The current meningococcal vaccination strategy in China could effectively prevent the disease at a low cost, but with limited serogroup coverage. Strategies using MPV-4, MCV-AC, or MCV-4 could increase health benefits at a substantial cost, and might become cost-effective if vaccine prices decrease.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10865926/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139724675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Performance evaluation on vaccination rates monitoring report system of Shenzhen, China. 中国深圳市疫苗接种率监测报告系统绩效评估。

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-01-12 DOI: 10.1080/21645515.2024.2302220

Linxiang Chen, Ziqi Wang, Xiaojun Zheng, Fangfang Lu, Huawei Xiong, Jing Liao, Chunmiao Peng, Kangming Chen, Wenli Zhang, Yucheng Xu, Lina Duan

{"title":"Performance evaluation on vaccination rates monitoring report system of Shenzhen, China.","authors":"Linxiang Chen, Ziqi Wang, Xiaojun Zheng, Fangfang Lu, Huawei Xiong, Jing Liao, Chunmiao Peng, Kangming Chen, Wenli Zhang, Yucheng Xu, Lina Duan","doi":"10.1080/21645515.2024.2302220","DOIUrl":"10.1080/21645515.2024.2302220","url":null,"abstract":"To evaluate the performance of \"Vaccination Rates Monitoring Report System\" implemented by Shenzhen CDC, we conducted an analysis of the data quality and identify key areas for system improvement. Following evaluation guidelines provided by WHO and United States CDC, we established six evaluation attributes: representativeness, simplicity, acceptability, data reliability, stability and timeliness. In eastern, central and western regions of Shenzhen, we selected one district from each region, of which the local CDC and ten CHSCs under jurisdiction were chosen for evaluation. On-site inspections, questionnaires survey and interviews were utilized for data collection, while the Likert scale method was used for attributes rating evaluation. A total of 70 participants were surveyed, consisting of 60 CHSCs and 10 CDCs staff. The gender ratio was 1:2.5 (males to females), with the majority falling within the 25-34 age range (46%). Most participants held full-time positions (80%) and had more than 5 years of work experience (62%). The system achieved 100% coverage of all CHSCs and CDCs (100%). The cumulative percentage scores for the overall favorable options of simplicity, acceptability, data reliability, stability, and timeliness were 79%, 85%, 73%, 50%, and 71% respectively. The system operates normally with strong representativeness. Acceptability was rated as \"good.\" Simplicity, data reliability, and system timeliness were rated as \"average,\" while system stability was rated as \"poor.\" Based on these survey results, developers should urgently investigate reasons for poor stability, particularly addressing concerns from CHSCs users. Additionally, the issues and shortcomings identified in other attributes should also be gradually improved.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10793700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139425815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

"Why has this new vaccine come and for what reasons?" key antecedents and questions for acceptance of a future maternal GBS vaccine: Perspectives of pregnant women, lactating women, and community members in Kenya. "为什么会有这种新疫苗，原因是什么？"接受未来孕产妇 GBS 疫苗的关键前因和问题：肯尼亚孕妇、哺乳期妇女和社区成员的观点。

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-02-12 DOI: 10.1080/21645515.2024.2314826

Rupali J Limaye, Prachi Singh, Berhaun Fesshaye, Clarice Lee, Jessica Schue, Ruth A Karron

{"title":"\"Why has this new vaccine come and for what reasons?\" key antecedents and questions for acceptance of a future maternal GBS vaccine: Perspectives of pregnant women, lactating women, and community members in Kenya.","authors":"Rupali J Limaye, Prachi Singh, Berhaun Fesshaye, Clarice Lee, Jessica Schue, Ruth A Karron","doi":"10.1080/21645515.2024.2314826","DOIUrl":"10.1080/21645515.2024.2314826","url":null,"abstract":"Group B streptococcus (GBS) is a leading global cause of neonatal sepsis and meningitis, stillbirth, and puerperal sepsis. While intrapartum antibiotic prophylaxis (IAP) is a currently available GBS disease prevention strategy, IAP is programmatically complex to implement, precluding use in low- and middle-income countries. In Kenya, 2% of stillbirths are attributable to GBS infection. Two maternal GBS vaccines are in late-stage clinical development. However, licensure of a maternal GBS vaccine does not translate into reduction of disease. We conducted 28 in-depth interviews with pregnant people, lactating people, and community members across two counties in Kenya to better understand the attitudes and informational needs of primary vaccine beneficiaries. We identified two emerging themes from the data. The first focused on antecedents to maternal GBS vaccine acceptability. The most common antecedents focused on the vaccine's ability to protect the baby and/or the mother, followed by community sensitization before the vaccine was available. The second key theme focused on questions that would need to be addressed before someone could accept a maternal GBS vaccine. Three key categories of questions were identified, including vaccine safety compared to vaccine benefits, who gets the vaccine, and how the vaccine works. Realizing the potential benefits of a future GBS maternal vaccine will require a multifactorial approach, including ensuring that communities are aware of GBS-related harms as well as the safety and effectiveness of a maternal GBS vaccine. Our study contributes to informing this multifactorial approach by elucidating the attitudes and concerns of key populations.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10863339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139724672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-based COVID-19 vaccination and willingness to pay: A post-pandemic review. 基于成本的 COVID-19 疫苗接种和支付意愿：大流行后的回顾。

IF 4.8 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-02-15 DOI: 10.1080/21645515.2024.2313860

Li Ping Wong, Hai Yen Lee, Haridah Alias, Gregory Zimet, Tongyu Liu, Yulan Lin, Zhijian Hu

{"title":"Cost-based COVID-19 vaccination and willingness to pay: A post-pandemic review.","authors":"Li Ping Wong, Hai Yen Lee, Haridah Alias, Gregory Zimet, Tongyu Liu, Yulan Lin, Zhijian Hu","doi":"10.1080/21645515.2024.2313860","DOIUrl":"10.1080/21645515.2024.2313860","url":null,"abstract":"The primary objective of this paper is to serve as a valuable resource for policymakers who are confronted with the evolving landscape of the coronavirus disease 2019 (COVID-19), considering both free and cost-based vaccination approaches. The potential consequences of shifting from free to cost-based vaccination are explored, encompassing its impact on global vaccine equity and prioritization, economic well-being, healthcare systems and delivery, public health policies, and vaccine distribution strategies. Examining past studies on willingness to pay for the initial COVID-19 vaccine dose and booster shots provides insights into how individuals value COVID-19 vaccinations and underscores the significance of addressing issues related to affordability. If COVID-19 vaccinations incur expenses, using effective communication strategies that emphasize the importance of vaccination and personal health benefits can increase willingness to pay. Making COVID-19 vaccines accessible through public health programs or health insurance can help alleviate financial barriers and increase vaccination rates.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10877984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139742444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0